Doxorubicin hydrochloride (liposomal) + Filgrastim + Bleomycin sulfate + Vincristine sulfate
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sarcoma, Kaposi
Conditions
Sarcoma, Kaposi, HIV Infections
Trial Timeline
— → Aug 1, 1998
NCT ID
NCT00001059About Doxorubicin hydrochloride (liposomal) + Filgrastim + Bleomycin sulfate + Vincristine sulfate
Doxorubicin hydrochloride (liposomal) + Filgrastim + Bleomycin sulfate + Vincristine sulfate is a phase 2 stage product being developed by Amgen for Sarcoma, Kaposi. The current trial status is completed. This product is registered under clinical trial identifier NCT00001059. Target conditions include Sarcoma, Kaposi, HIV Infections.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00001059 | Phase 2 | Completed |
Competing Products
20 competing products in Sarcoma, Kaposi